Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Julphar
Covington
Cipla
Mallinckrodt
Express Scripts

Generated: August 22, 2019

DrugPatentWatch Database Preview

Patent: 7,446,124

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,446,124
Title:Wortmannin analogs and methods of using same in combination with chemotherapeutic agents
Abstract: Novel wortmannin analogs and their use in inhibiting PI-3-kinase activity in mammals and the treatment or prevention of cancer and tumor formation in a subject are described herein. Preferably, the wortmannin analogs may be administered with other chemotherapeutic agents in the treatment of cancer.
Inventor(s): Kirkpatrick; Lynn (Tucson, AZ), Powis; Garth (Tucson, AZ), Wipf; Peter (Pittsburgh, PA)
Assignee: Prolx Pharmaceuticals Corp. (Houston, TX) The University of Pittsburgh (Pittsburgh, PA) Arizona Board of Regents, Acting on Behalf of the University of Arizona (Tucson, AZ)
Application Number:11/178,553
Patent Claims:see list of patent claims

Details for Patent 7,446,124

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26 ➤ Sign Up Prolx Pharmaceuticals Corp. (Houston, TX) The University of Pittsburgh (Pittsburgh, PA) Arizona Board of Regents, Acting on Behalf of the University of Arizona (Tucson, AZ) 2024-07-09 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26 ➤ Sign Up Prolx Pharmaceuticals Corp. (Houston, TX) The University of Pittsburgh (Pittsburgh, PA) Arizona Board of Regents, Acting on Behalf of the University of Arizona (Tucson, AZ) 2024-07-09 RX search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18 ➤ Sign Up Prolx Pharmaceuticals Corp. (Houston, TX) The University of Pittsburgh (Pittsburgh, PA) Arizona Board of Regents, Acting on Behalf of the University of Arizona (Tucson, AZ) 2024-07-09 RX Orphan search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25 ➤ Sign Up Prolx Pharmaceuticals Corp. (Houston, TX) The University of Pittsburgh (Pittsburgh, PA) Arizona Board of Regents, Acting on Behalf of the University of Arizona (Tucson, AZ) 2024-07-09 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Cantor Fitzgerald
US Army
AstraZeneca
Harvard Business School
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.